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Executive Summar y
The purpose of this study is to investigate the relative 
value of the female condom for HIV prevention within 
heterosexual relationships in the developing world. In 
the last ten years, the world has witnessed both historic 
financial commitments to HIV/AIDS and new prevention 
options, including biomedical prevention research, 
male circumcision, and a dramatic scale-up of voluntary 
counseling and testing. At the same time, where HIV 
remains at epidemic levels in many countries, there has 
been a growing commitment to treatment access alongside 
prevention programs. However, portions of populations, 
particularly youth and women, remain highly vulnerable to 
HIV infection. Accordingly, the global health community 
can benefit from a better understanding of how existing 
prevention options should be effectively and efficiently 
delivered to reduce HIV in the developing world. This  
report provides guidance for the global health community 
for considering how the female condom fits within the set  
of prevention interventions currently available.
The nonprofit consulting firm FSG Social Impact Advisors 
and academic researchers Elliot Marseille (Health Strategies 
International) and James G. Kahn (University of California, 
San Francisco) conducted this study on behalf of the Bill 
& Melinda Gates Foundation. The authors undertook four 
modules of research: a landscape analysis (literature review 
of the major articles, reports, evaluations, and conference 
agendas on the female condom during the last 15 years); 
programmatic analysis (comparative review of 14 female 
condom programs across 10 different countries in the 
developing world); stakeholder analysis (conversations with 
more than 50 implementers, donors, manufacturers, and 
experts); and a cost-effectiveness analysis (technical modeling 
of the cost-effectiveness of the female condom compared 
with the male condom and other prevention strategies).  
The research team conducted these analyses in 2007.  
Study methods, interim findings, and conclusions were 
reviewed with health economists, the foundation, and  
female condom stakeholders.
The female condom was launched in the developing world in 
the mid-1990s and is now an important prevention tool for 
dozens of countries’ HIV prevention programs. A great deal 
of research was conducted prior to launch to test its efficacy 
and acceptability with particular groups. Initial feedback 
about the female condom by users in the developing world 
was mixed, with some hailing it as a boon to women’s 
empowerment and others finding it challenging to use. 
Distribution of the female condom has varied throughout 
the developing world, with high volumes in Brazil, South 
Africa, and Zimbabwe. Interpersonal communication 
and provider training are hallmarks of female condom 
programming. The female condom has benefited from 
innovation with a new product already on the market, and 
others on the way. To date, more than 140 million units have 
been distributed, with a large proportion of delivered in the 
developing world for HIV prevention. 
This is the widely known and accepted story about the 
female condom since its initial launch in the developing 
world. But this story has also been marked by a great deal 
of debate — a remarkable number of official dialogues dot 
the female condom timeline. Some stakeholders question 
the high commodity cost of the female condom compared 
with the male condom and point to the cost gap as a key 
reason for varied political support by developing country 
governments. But there are women and men who will not 
use the male condom, and offering protection, albeit at a 
higher cost, may be an appropriate investment aimed at 
decreasing risky sex acts. The female condom is considered 
an important empowerment tool for women in its own right, 
allowing individual women to better negotiate safer sex and 
societies to discuss the imbalance in sexual power between 
men and women. The perspective that the female condom 
is the only female-initiated prevention tool for women has 
created a strong advocacy base for promoting the product as 
a right for women in developing countries. Health impacts, 
costs, and human rights are intertwined at the core of the 
female condom debate.  
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There is no better time to enter this dialogue, as new 
momentum for the female condom builds with increased 
distribution, new female condom products, and new 
advocacy efforts, all seen in the last two years. Other 
prevention technologies, such as an AIDS vaccine or a 
microbicide, are on the horizon, but recent trials suggest 
that any evidence of success for either technology will not 
be seen for at least five years. This study offers new findings 
and recommendations for helping the female condom 
community move with renewed urgency toward more 
concerted action as existing HIV prevention efforts  
are reinforced. 
The study provides three key findings. First, the female 
condom field lacks a consistent definition of success.  
Current definitions variously include number of units 
distributed, new cases of HIV averted, and strengthened 
sexual rights for women. Without agreement on success 
for this product, there is a tremendous risk that the debates 
about the female condom will only continue and more 
urgent action may be delayed. Second, the female condom 
is much less cost-effective than the male condom and other 
HIV prevention options based on analytical modeling. 
Reducing high commodity costs has been the focus of the 
field to date. In addition to commodity costs, the study’s 
cost-effectiveness analysis identifies male and female 
condom marginal costs (the cost of adding one more male 
or female condom to a program), substitution rates, and 
targeting to discordant couples as the key factors to reduce 
costs. Disciplined attention to these levers may bring about 
improved cost-effectiveness. Third, female empowerment, 
which may be engendered through the use of the female 
condom, is central to effective HIV prevention, but such 
benefits are difficult to quantify.   
The authors conclude that the female condom is a necessary 
tool for HIV prevention, specifically for those who cannot 
or will not use the male condom. A more sophisticated, 
program-centered approach is recommended to increase  
the impact of the female condom for HIV prevention.  
The cornerstone of this approach is a new definition of 
success for the female condom: 
Targeting has always been prioritized for the female 
condom, but an even more sophisticated approach, 
termed “smarter programming” in this study, is needed. 
Smarter programming attempts to target groups and put 
in place interventions that optimize the levers mentioned 
earlier: reduced commodity and marginal costs of the 
female condom, reduced substitution rates with the male 
condom, and focus on discordant couples, where they can 
be identified. The report provides one scenario example for 
how these levers might work together, but programmers are 
encouraged to think creatively and act in a highly disciplined 
fashion with regard to their own local circumstances. A 
female condom Success Fund is recommended to motivate 
country programs to identify target audiences where the 
levers can be maximized.     
A consequence of such smarter programming is a move 
away from blanket approaches to female condom delivery. 
Smarter programming should replace calls to normalize or 
mainstream the female condom in the developing world. 
Well-intentioned efforts to measure the success of the female 
condom through distribution numbers or mainstream 
awareness may expand the product’s relevance from a sexual 
rights perspective, but they could also diminish impact, in 
terms of directing the product to those who need it most. 
Further, based on the cost-effectiveness analysis conducted in 
this study, programs that do not pursue the tenets of smarter 
programming will misuse valuable resources. 
The findings and recommendations of this study point 
to a new trajectory for the female condom — specifically, 
an approach in which “more is better” to “smarter 
programming” for more cost-effective impact. This shift 
reflects an improved understanding of where the female 
condom can most likely prevent new cases of HIV and 
produce a higher return on investment for donors and 
program managers alike. 
A New Definition for Female Condom Success in the Developing World
The female condom should result in averted cases of HIV/AIDS and unwanted pregnancies that could not be more 
readily achieved through alternative approaches, notably additional promotion of male condoms, and be distributed in 
a	manner	that	is	as	cost-effective	as	possible.		Additional	benefits,	such	as	improved	relationships	with	marginal	groups	
or expanded women’s rights, should be no more costly than when achieved by other interventions that bring about 
similar results.  
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I. INTRODUCTION
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I .  Introduction
Nearly 20 years into the HIV/AIDS crisis in the 
developing world, the global health community now 
has a broad set of tools for helping prevent new HIV 
infections. With such a range of prevention interventions, 
there is a need for analysis to understand when to employ 
each tool given various factors such as transmission 
dynamics, cultural factors, and cost-effectiveness. In 
February 2007, the Bill & Melinda Gates Foundation 
engaged FSG Social Impact Advisors1 to conduct an 
investment case analysis on the female condom in the 
developing world. 
The purpose of this paper is to shed light on the relative  
value of the female condom for averting HIV/AIDS 
and unwanted pregnancies in the context of other 
interventions that are in use, such as the male condom. 
FSG conducted a multifaceted analysis of the female 
condom for the foundation, including assessments of 
issues of supply and demand in the developing world, 
stakeholder perceptions, viability of new product designs, 
and cost-effectiveness modeling. This particular paper 
focuses on four questions from the larger body of  
FSG’s work:
1. What is the current status of female   
 condom distribution and uptake as an HIV  
 prevention intervention?
2. How is success defined for the  
 female condom?
 
3. Under what scenarios, if any, can the  
 female condom be cost-effective, compared  
 with the male condom and other HIV   
 prevention interventions?
 
4. What are the recommendations for donors  
 and implementers based on this analysis?
  1
 
FSG Social Impact Advisors is a nonprofit consulting firm that provides advice and ideas in the areas of  strategy and evaluation for the social sector.
Research Methodology
Research	activities	informing this work include: 
• Landscape analysis: Literature review of  
 the major articles, reports, evaluations,   
 and conference agendas
 • Stakeholder analysis: Conversations  
 with more than 50 implementers, donors,   
 manufacturers, and experts
 • Programmatic analysis: Comparative  
 review of 14 female condom programs  
 across 10 different countries
• Marginal cost-effectiveness analysis: Technical  
 modeling of the marginal cost-effectiveness   
 of the female condom compared with the   
 male condom
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This paper uses evidence from actual programs and  
cost-effectiveness modeling to answer these questions  
and develop recommendations for donors, program 
managers, and researchers to effectively deploy the female 
condom as part of comprehensive HIV prevention strategies. 
To supplement a team of consultants well-versed in global 
health strategies, FSG partnered with Elliot Marseille2 of 
Health Strategies International and James G. Kahn from the 
University of California, San Francisco (UCSF), to develop 
a comprehensive model for assessing the cost-effectiveness of 
the female condom relative to the most widespread barrier 
method available, the male condom. The cost-effectiveness 
study acknowledges that the male condom and the female 
condom are different and not always substitutable products, 
and that they are at different phases in their life cycles and 
serve different markets. 
For donors, governments, and program managers who 
consider cost-effectiveness an important criterion in 
the allocation of resources, this study offers specific 
recommendations about how to best deploy the female 
condom. However, the study also recognizes that cost-
effectiveness in preventing HIV/AIDS or averting  
pregnancies is only part of the picture. For example, 
HIV prevention depends on greater women’s empowerment, 
an outcome that some attribute to the education and 
negotiation skills that are part of successful female condom 
programs. Other goals may be furthered by introducing 
the female condom through relationship-building with 
marginalized groups or by studying its introduction to 
inform a future microbicide launch. These benefits were not 
quantified in this cost-effectiveness analysis because of the 
dearth of available data.
This report is not meant to be a definitive or exhaustive 
analysis of the female condom. FSG has limited its research 
scope to the developing world. Also, while FSG has reviewed 
dozens of articles on the female condom, the literature on 
this product continues to expand.    
FSG Social Impact Advisors is a strategy consulting firm 
that helps funders make the best use of resources for the 
greatest possible social impact. The analyses offered here are 
intended to help guide funding decisions and programmatic 
approaches. FSG does not implement programs, fund them, 
or conduct advocacy; this neutral position can bring new 
clarity to the future of the female condom. In the interest 
of full disclosure, FSG Managing Director Kyle Peterson, a 
primary author of this study, launched the female condom as 
Population Services International’s (PSI) country director in 
Zimbabwe in 1997/1998. While stating that caveat, we hope 
that FSG’s understanding of the dynamics on the ground 
and all the players involved with this product makes this 
study a more pragmatic and provocative product in the end.   
 
  2
 
Elliot Marseille authored a 2001 study titled “Cost-effectiveness of  the Female Condom in Preventing HIV and STDs in Commercial Sex Workers in Rural South Africa.”
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I I .  Si tuat ion Analysis
The global disease burden of HIV/AIDS is staggering, 
accounting for 39.5 million infections and 2.8 million deaths 
worldwide in 2006.3 Despite promising efforts to increase access 
to treatment and prevention programs, the number of people 
living with HIV and deaths attributable to AIDS continues to 
grow. During the past two decades, the number of people living 
with HIV has increased in every region of the world. However, 
the burden of HIV/AIDS remains highest in sub-Saharan Africa, 
a region that accounts for only 10% of the world’s population 
but over 60% of HIV/AIDS infections. Seventy-two percent of 
deaths in sub-Saharan Africa are due to AIDS.4
Women in particular suffer a disproportionate impact of the 
HIV/AIDS disease burden, especially women in highly afflicted 
sub-Saharan Africa. In this region, three women are infected with 
HIV for every two men. Among young people ages 15 to 24, 
the magnitude of this disparity is even greater, with three young 
women infected for every young man.5 A number of factors 
place women at heightened risk for contracting HIV, including 
the threat of violence (both in relationships and in conflict 
situations), lack of economic independence, cultural norms and 
expectations, biological differences, and work in the sex trade.6 
In the face of this crisis, a number of prevention interventions 
are available to developing world health leaders, multilateral 
institutions, donors, and implementers. The ABCs of 
prevention — abstinence, fidelity (be faithful or reduce the 
number of partners), and male condom use — have served as 
the cornerstone of prevention efforts for the last quarter century. 
Other prevention interventions include voluntary counseling 
and testing (VCT), blood safety, prevention of mother-to-child 
transmission (PMTCT), school-based HIV education programs, 
outreach to sex workers, mass media programs, screening and 
treatment of sexually transmitted infections, and, most recently, 
adult male circumcision. Most governments and donors offer a 
package of these services, emphasizing some more than others, 
with varied approaches that include the public and private 
sectors, community representatives, medical practitioners, the 
media, religious organizations, and policy influence, just to 
name a few.
Given women’s increased risk of contracting HIV and the 
known difficulties of negotiating male condom use in cultures 
in which requests for protected sex are often interpreted as signs 
of infidelity or mistrust, there is great need for a safe and effective 
alternative to the male condom.  To date, the female condom 
is the only technology available that women can turn to as an 
alternative to the male condom. A number of organizations, 
including the International Partnership for Microbicides, 
the Contraceptive Research and Development Program 
(CONRAD), and the Population Council, have partnered 
with pharmaceutical firms to develop a microbicide that can 
be inserted by women in gel or perhaps ring form; however, 
two Phase III trials have not shown efficacy and the trials have 
been halted. Newer microbicides in development are based on 
different scientific approaches, but trials of these products are a 
few years away and their development and commercialization 
could take a decade or more.  
3 UNAIDS “AIDS Epidemic Update,” December 2006.    
4 UNAIDS “AIDS Epidemic Update,” December 2006.
5 UNAIDS “AIDS Epidemic Update,” December 2006.
6 UNAIDS “AIDS Epidemic Update,” December 2006.        
State of the Male Condom
The male condom has become a ubiquitous and 
important method in the prevention of HIV/AIDS. 
According to the United Nations Population Fund 
(UNFPA), approximately 11 billion condoms were 
distributed	in	2007.	However,	there	are	still	significant	
obstacles to using male condoms and demand is far 
from	satisfied	in	the	developing	world.		
UNFPA further states, “Many people at risk of HIV/STIs 
do not use condoms. Some do not realize that they 
are at risk of infection or understand how to protect 
themselves. Some worry about how their partners 
will react if they suggest using condoms, or they 
believe condoms will make sex less enjoyable. Some 
are discouraged by the social stigma associated with 
condoms.	Some	have	difficulty	finding	a	convenient	and	
affordable source of supply. Effective condom programs 
must overcome all of these potential barriers by:
• Creating a reliable supply of quality condoms  
 by improving stock management and storage  
 conditions;
• Making condoms readily available even for   
 spontaneous users;
• Promoting demand for condoms by raising 
 awareness of HIV/STI risks and teaching people 
 how to use condoms correctly and consistently;
• Working to eradicate the social stigma associated 
 with condoms; and
• Promoting a supportive environment by 
 advocating for HIV prevention and condom  
 use in the broader community.”
(UNFPA/WHO/PATH, 2005, “Condom Programming for HIV Prevention,  
a Manual for Service Providers.”)
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The female condom was introduced in the United States in 
1992, and the decision by the government of South Africa 
in 1995 to include the female condom as part of its early 
prevention activities effectively launched the female condom 
in the developing world.7 Public and private sector distribution 
in Zimbabwe followed in 1997. Over the past decade, the 
female condom has experienced modest growth in distribution 
in the developing world, with the majority of female condoms 
distributed by large-scale public sector programs. To date, more 
than 140 million units have been sold.8  
The Female Health Company (FHC), the primary manufacturer 
of the female condom, introduced its first product, the FC1, in 
1993. Consisting of a welded, prelubricated polyurethane sheath 
with flexible rings at each end, the FC1 has been marketed under 
a variety of brand names in more than 130 countries around 
the world. The FC1 was sold to governments and donors based 
on an agreement with the Joint United Nations Programme 
on HIV/AIDS (UNAIDS) at approximately $0.80 per unit,9 
depending on the volume purchased. The FC1 was the only 
female condom on the market until 2002, when the Dr. Reddy’s 
company launched an additional product, constructed of a 
prelubricated latex pouch with a polyurethane sponge insertion 
and flexible outer ring. Unlike the FC1, the Dr. Reddy’s female 
condom has not received US FDA approval, nor has it been 
procured by any public sector agency. In 2005, the Female 
Health Company introduced the FC2, the replacement for 
the FC1, made of a synthetic rubber (nitrile) material and 
manufactured at lower costs. The FC2 is sold through similar 
government and multilateral arrangements at approximately 
$0.57 per unit.10 (Male condoms, by comparison, are purchased 
by the same institutions for approximately $0.03 per unit.) The 
FC2 has been approved and recommended by the WHO and is 
currently under review for approval by the US FDA. A number 
of other female protection products are available, such as the 
Natural Sensations panty condom, but they have not gained 
prominence among large private or public procurers. 
Several additional female condom products are currently in 
development. The Program for Appropriate Technology in 
Health (PATH) has developed a new female condom that is 
inserted like a tampon. Made of polyurethane, PATH’s 
Woman’s Condom consists of a flexible outside ring that 
includes a dissolvable insertion capsule with stabilizing foam 
shapes, plus separate lubricant. The Belgium Female Condom, 
developed by MEDITEAM, is made of natural latex and is 
designed to cover the entire vulva and base of the penis. The 
Silk Parasol panty condom, developed by the Silk Parasol 
Corporation (U.S.), is a reusable panty with refill condoms. 
These products are in various stages of development and 
regulatory approval, and their ultimate availability is dependent 
upon more funding. It will be several years before any of them 
are on the market.11 
Several organizations are involved in supporting, researching, 
and implementing the female condom including donors, 
researchers, product developers, social marketers, and various 
public sector health systems. Key donors and multilateral 
organizations that have been instrumental in providing female 
condom funding include UNFPA, US Agency for International 
Development (USAID), UK Department for International 
Development (DFID), and the Netherlands Development 
Cooperation.12 Organizations such as the World Population 
Foundation (WPF), Family Health International (FHI), and the 
Reproductive Health Research Unit (RHRU) play a significant 
role in advocacy and research related to the female condom. Key 
implementers include Population Services International (PSI), 
Marie Stopes International (MSI), and DKT International. 
These three organizations apply social marketing or community 
distribution techniques in the private sector and currently 
support female condom distribution programs in twenty, four, 
and two countries, respectively. Organizations such as Ghana’s 
Society for Women and AIDS in Africa (SWAA) and the 
Hindustan Latex Family Planning Promotion Trust in India are 
also working to promote the female condom. Implementation 
 7 Mantell, JE, Scheepers, E, Karim, QA. 2000. “Introducing the Female Condom through the Public Health Sector: Experiences from South Africa,” AIDS Care. 12(5):  
  589–601. 
 8 Female Health Company.  
 9 At current USD – UK Sterling exchange rates.
10 Female Health Company. FHC estimates that at distribution levels of  180 million units, the cost of  the FC2 could drop to $0.30 per unit.
11 Beksinska, M. 2005. “The Female Condom: Reviewing the Past and Exploring Future Potential.” Priorities Conference in Reproductive Health and HIV, Stellenbosch,  
  South Africa. (PowerPoint presentation.)
12 Other donors include WHO; CONRAD; The Global Fund Against AIDS, TB and Malaria; DANIDA; the Hewlett Foundation; and the Lemelson Foundation, among others.    
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in the public sector is largely supported by ministries of health, 
with the largest programs in Brazil, South Africa, and India, 
and smaller programs in Zimbabwe, Ghana, and Namibia. 
Important advocates of the female condom include the UNFPA 
Global Female Condom Initiative, the Dutch Universal Access 
Campaign, and the Center for Health and Gender Equity’s 
Prevention Now! campaign. 
13 Hoke, TH, Feldblum, PJ, Vandamme, K, et al. 2007. “Temporal Trends in Sexually Transmitted Infection Prevalence and Condom Use Following Introduction of  the  
  Female Condom to Madagascar Sex Workers.” International Journal of  STI and AIDS. 18(7): 461-6.
14 Feldblum, PJ, Kuyoh, MA, Bwayo, JJ, et al. 2001. “Female Condom Introduction and Sexually Transmitted Infection Prevalence: Results of  a Community Intervention  
  Trial in Kenya.” AIDS. 15(8): 1037-44.
15 Musaba, E, Morrison, CS, Sunkutu, MR, Spruyt, A, Chomba, AB. “Long-term Use and Acceptability of  the Female Condom among Couples at High Rrisk of  HIV  
  in Zambia.” Int Conf  AIDS. 1996 Jul 7-12; 11:238 (abstract no. Th.C.430).
16 Hoke, TH, Feldblum, PJ, Vandamme, K, et al. 2007. “Temporal Trends in Sexually Transmitted Infection Prevalence and Condom Use Following Introduction of  the  
  Female Condom to Madagascar Sex Workers.” International Journal of  STI and AIDS. 18(7): 461-6.
17 Fontanet, A, Saba, J, Chandelying, V, et al. “Protection against STDs by granting sex workers in Thailand the choice of  using the male or female condom.”
18 Musaba, E, Morrison, CS, Sunkutu, MR, Spruyt A, and Chomba, AB. “Long-term Use and Acceptability of  the Female Condom among Couples at High Risk of  HIV in  
  Zambia.” Int Conf  AIDS. 1996 Jul 7-12; 11:238 (abstract no. Th.C.430).
Exhibit 1: Estimated Total Distribution of Female Condoms (1997-2007)
Source: Female Health Company (FHC) 
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During the last ten years, studies have shown that introduction 
of the female condom can increase the total number of protected 
sex acts,13 increase consistency of condom use among female 
sex workers (FSWs),14 and decrease unprotected sex acts.15 Ten 
studies evaluating the health impact of the female condom were 
reviewed for this report, including Theresa Hoke’s Madagascar 
study,16 the Thailand sex worker study,17 and the Zambia study 
of couples in STI clinics.18 
14 © 2008 FSG Social Impact Advisors
Exhibit 2: Timeline of female condom activity
Source: “The female condom: Reviewing the past and exploring future potential,” RHRU, 2005; FSG analysis
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Signs of New Momentum for the Female Condo
The female condom is at an inflection point after roughly 15 
years of existence in the developing world. Moving from an early 
acceptability stage in the early 1990s, to market introduction in 
the mid-1990s, to a period of unmet or questioned expectations 
at the beginning of this decade, the female condom is receiving 
increased attention through new products, increased distribution, 
and additional funding, as seen in Exhibit 2. The global health 
community continues to invest funds in the effort to develop 
new technologies to prevent HIV/AIDS, such as vaccines and 
microbicides. While male circumcision gains interest, funding, 
and momentum, there is also discussion about re-emphasizing 
attention to women’s methods and needs. This is an opportune 
time to review what has been learned about the female condom 
to date and to reflect upon how these lessons can inform future 
decision-making in order to ensure that female condoms 
are provided as cost-effectively as possible, while providing 
maximum protection against new HIV cases. 
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III. PROGRAMMATIC AND     
 STAKEHOLDER ANALYSIS
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III. Programmatic and  
  Stakeholder Analysis
FSG conducted programmatic analysis to assess country-level 
distribution and promotion and stakeholder analysis to capture 
perceived barriers to female condom support as reported by 
donors, implementers, and advocates. The programmatic 
analysis validated a set of best practices known to the female 
condom community and reemphasized the importance of 
targeting. The stakeholder analysis identified a key issue missing 
in the decade-long dialogue about the female condom: a clear 
and shared definition of success that incorporates the issues of 
health impact, cost-effectiveness, and sexual rights. Without such 
agreement on a definition of success, opportunities to implement 
the female condom may be missed and donors may maintain a 
wait-and-see attitude about its use.
A. Programmatic Analysis 
FSG collected data from 14 female condom programs 
across 10 different countries and seven different organizations, 
and conducted interviews with implementers, both at their 
headquarters and in the field. FSG focused on understanding 
what drives successful, sustained female condom uptake. 
The programs selected for analysis represent both high-profile, 
established programs and newer, emerging ones, and they were 
chosen to provide a mixed sample with regard to geography, 
organization, delivery approach, and types of lessons learned. 
Programs were evaluated based on their own stated goals, as 
indicated by the population groups defined as their targets. 
The programs analyzed were:
• DKT: Brazil, Mexico
• Government (Ministry of Health): South Africa, Brazil
• Hindustan Latex Family Planning Promotion Trust: India
• MSI: Uganda, Namibia, Mongolia
• Society for Women and AIDS in Africa (SWAA): Ghana
• PSI: Myanmar, South Africa, Tanzania, Zambia, Zimbabwe
Above all else, FSG’s analysis confirms the importance of 
targeting the female condom. Other findings include the 
importance of interpersonal communication and peer education 
for female condom promotion and the observation that program 
managers make do with highly constrained budgets. 
• FSG’s analysis of the 14 country programs underlines  
 the importance of identifying specific audiences and  
 designing programs to reach them. Five of the assessed  
 programs emerged as doing a particularly effective job of  
 identifying target audiences and designing appropriate  
 programs to meet their needs. Such customized programs  
 for targeted audiences can result in strong “penetration”  
 (number of units distributed per person within a designated  
 population). PSI Myanmar, for example, had relatively  
 low annual distribution, but its penetration of the stated  
 target audiences — men who have sex with men (MSMs)  
 and female sex workers (FSWs) — was dramatically better  
 than in the MSI Uganda program, where target groups 
 were not as well-defined.
• As mentioned in the literature and confirmed in this  
 analysis, specific target audiences require specific   
 distribution outlets for penetration to occur.  
 Use of nontraditional outlets – such as hair salons, truck  
 stops, universities, workplaces, female sex worker locations,  
 and HIV/AIDS networks and support groups — is often  
 necessary for effective distribution to hard-to-reach 
 target groups. For instance, the goal of PSI’s program in  
 Zimbabwe has not been national coverage or expansion, 
 but rather a concentration on well-researched target  
 groups, including FSWs, women who know they are  
 HIV-positive, university women, and low-income women  
 in steady relationships. An estimated 80% of the program’s  
 female condom distribution comes through such channels,  
 with over half of sales coming from beauty salon programs  
 in which stylists provide the product, along with 
 education and training, to their clients. Similarly, in  
 addition to utilizing beauty salons, PSI Zambia also  
 conducts outreach to high-risk groups such as truck 
 drivers at truck stops and miners at copper mines. 
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• The programs that were the most adept at targeting  
 adopted product positioning appropriate for their  
 selected target groups. For instance, the PSI Zambia  
 and MSI Namibia programs have adopted dual 
 positioning, emphasizing HIV/AIDS prevention for  
 FSWs and pregnancy prevention for married couples.  
 To avoid stigmatization within the general population,  
 PSI Zimbabwe has positioned the female condom for  
 pregnancy prevention despite focusing its distribution  
 strategy on high-risk groups, such as FSWs and HIV- 
 positive women. 
Table 1: Quantitative summary of five female condom programs with highest  
penetration based on stated target populations
Source: PSI data, MSI data, MOH Brazil data, FSG interviews and analysis
20002001199719952003Program Launch
2.9M374K2.2M410K359KEstimated Size of Target Population
FSWs; HIV-
positive women;
Drug users;
Partners of drug
users
FSWs; MSM;
Working class
men and women
FSWs; HIV-
positive women;
University women;
Low-income
women in
relationships
FSWs; Young,
married, urban
couples
FSWs, MSMStated Target Groups
Free$0.27$0.01-0.24**$0.12$0.02-0.05Price to the Consumer
8424592
Total Population Penetration (Average Annual
Distribution / 1,000 Total Population)
$4,231
$12,639
$8,399
$25,196
$1.29
$152,624
$457,871
248
0.89
89,055
356,220
PSI Myanmar
$8,017
$64,133
$14.082
$112,660
$0.81
$132,804
$1,062,434
266
0.53
109,125
1,309,496
PSI Zambia
$34,100
$306,902
$53,180
$478,621
$0.63
$410,995
$3,698,959
270
0.31
590,703
5,907,034
PSI Zimbabwe
$25,000
$150,000
$42,000
$252,000
-
$227,679*
-
238
0.39
88,812
532,872
MSI Namibia
$3,000,000*
-
$2,000,000*
-
-
$8,000,000*
-
506
0.13
1,471,429
10,300,000
MOH Brazil
Average Annual Interpersonal Communication
Spend
Cumulative Spend on Interpersonal Communication
Average Annual Advertising/Promotion Spend
Cumulative Spend on Advertising/Promotion
Average Program Spend Per FC Distributed
Average Annual Program Spend
Cumulative Program Spend
Target Population Penetration (Average Annual
Distribution / 1,000 Target Population)
Growth in Annual Distribution (CAGR)
Average Annual Distribution
Cumulative FC Distribution
Quantitative Data
Notes: Spending on provider training is not broken out for PSI programs; these expenses are captured under other categories (e.g., local salaries, interpersonal
communication). One year of program spending data missing for Zambia (1998). Only one year of total program spend data available for Namibia.
* Based on 2006 data only.
** Price was originally set at $0.24 but has fallen to the equivalent of $0.01 more than once due to economic instability and inflation.
urce: PSI data, MSI data, MOH Brazil data, FSG interviews and analysis.
The following tables summarize high-level data from the analysis 
of female condom programs. Five programs are featured with the 
highest penetration based on stated target populations (average 
annual distribution/1,000 total population).
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B. Stakeholder Analysis
Conversations conducted by FSG with more than 50 
stakeholders with knowledge of and program experience with 
the female condom (donors, researchers, program managers) 
revealed support for the female condom but also the key fault 
lines in the debate about the product. Interviewed stakeholders 
focus on the issue of the female condom’s high commodity cost 
and low political support. 
Most interviewees identified the female condom as a product 
with long-term potential, claiming its unique value as the only 
effective, female-initiated method of preventing HIV, STIs, 
and pregnancy. A number of interviewees also highlighted the 
potential for the female condom to aid the introduction of other 
vaginally inserted products, including microbicides. As stated by 
one participant, “The female condom is absolutely crucial for the 
introduction of the microbicide. It’s critical that the female condom is 
19 FSG interviews.
20 FSG interviews.
Table 2: Qualitative summary of selected female condom programs analyzed
Sources: DKT, PSI, MSI, MOH South Africa, MOH Brazil, MOH Ghana, UNFPA, FSG analysis
Drug users
HighMediumMediumLowHighHighLowHighHighHighLevel of in -country
Advocacy
NoNoNoNoRecentlyYesMSM onlyYesYesNoActive targeting of men?
MOH,
Women and
AIDS
Support
Network
MOHNoneT-MARC(AED)PSIMOHNGOsOther NGOsDKTMOHOther FC programs
Distribution outlets
PrivatePrivatePrivatePrivatePublicBothPrivateBothPublicPrivateSector
Stated target groups
Pregnancy
prevention
Dual
positioning
HIV/AIDS
prevention
Dual
positioning
Dual
positioning
Dual
positioning
HIV/AIDS
prevention
DualHIV/AIDS
prevention
DualProduct positioning
1997199520011998199720012003200020001998Program launch
YesNoNoFormerly*YesNoNoYesYesNoDedicated FC sta?
YesYesNoFormerly*NoYesYesYesYesNoFocus on interpersonal
communication?
Not since
1997
NoNoFormerly*NoNot since
2001
NoYesNoNot since
2000
Use of mass media?
DKT Brazil MOHBrazil
MOH /
NGOs
Ghana
PSI
Myanmar
MSI
Namibia
MOH
South
Africa
PSI
Tanzania
PSI
Zambia
MSI
Uganda**
PSI
Zimbabwe
-
positioningpositioning
Notes: *PSI Tanzania no longer has funding to support programmatic eorts (only commodities); ** MSI ’s FC program in Uganda was shut down after 2004
Women in relationships HIV-positive women Sexually active women MSM OtherFSWsStated Target Groups
Beauty salons Mainstream shops VCT centers Other health clinics OtherPeer networksDistribution Outlets
training people who can talk about their sexual organs comfortably. 
I would really like to see some of the microbicide groups fund the 
female condom to learn from its lessons.” 19 
While interviewed stakeholders were generally positive about 
the female condom, they also articulated important notes of 
skepticism. Specifically, some interviewees questioned whether 
the female condom could be viable commercially and whether it 
is truly female controlled. According to one interviewee,
“The female condom is a product that is unlikely to ever reach mass 
appeal. It is even more difficult to use than the male condom, which 
is sufficiently difficult to use. The female condom needs a higher level 
of education and typically requires training to see continued use, 
which is often difficult to implement when resources are limited. 
Customer consultation is also culturally awkward in many countries. 
I don’t see it having sufficient volume to be commercially attractive as 
a product.” 20
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The interviewees, like the literature and meeting notes from 
the major consultations held over the last ten years, tended to 
focus on the challenges facing the female condom. Hurdles 
include inconsistent supply, product attribute challenges (such 
as noise and difficulty in use, loose fit, unsightliness), absence of 
provider support, the need for additional operational research, 
cultural barriers, and women’s lack of empowerment. Opinions 
have evolved with respect to these barriers. Where product 
attribute challenges were initially perceived as constraining 
adoption of the female condom, more recent discussions seem to 
prioritize the high commodity cost of the female condom with 
the corresponding low political and financial support that 
follows from it. To a lesser extent, interviewees also mentioned 
that limited education and training act as a significant barrier to 
increased uptake.  
• High commodity costs: The female condom’s current  
 commodity costs are more than 15 to 20 times higher 
 than those for the male condom ($0.80 for the FC1 and  
 $0.57 for the FC2 as compared with $0.03 or less for the  
 male condom). This difference exists in part because female  
 condoms require more complicated manufacturing   
 processes and more expensive raw materials.21 A 2004  
 consultation organized in London by the Global   
 Campaign for Microbicides (GCM) on behalf of the  
 Global Coalition on Women and AIDS described a  
 vicious cycle in which high commodity costs breed low  
 donor interest and limit procurement volumes, which  
 limits the ability to meet demand, which in turn   
 discourages additional interest, so that high commodity  
 costs persist. Recommendations for breaking this cycle  
 included catalyzing or subsidizing other product developers,  
 re-engaging on female condom re-use, and supporting large- 
 scale commodity purchase in a number of countries to  
 increase demand and ensure supply at lower unit costs.
• Low political and financial support: Laura Frost 
 describes a lack of global political and financial   
 commitment to the female condom. According to 
 Frost and others, many of the recommendations from 
 the earliest consultations on the female condom 
 have not been implemented or have only been partially  
 implemented because of the lack of a coordinating hub 
 for the female condom. In addition, family planning  
 groups, with the exception of UNFPA, have not pushed 
 the female condom as a contraceptive device, preferring  
 more affordable hormonal methods.22 A new report by 
 the Center for Health and Gender Equity reports that low 
 U.S.  political support for the female condom and simple  
 bureaucratic blockages have created serious barriers to  
 increased access to this product.23   
C. A Decade of Experience and  
 Dialogue without a Consistent   
 Definition of Success
Amidst the programmatic lessons learned and the series of 
consultations undertaken since the female condom’s launch 
in the developing world, there has been limited discussion 
about what constitutes success for the female condom. Some 
stakeholders, such as PSI, view the female condom as a 
complement to the male condom and consider its benefits 
in terms of incremental cases of HIV prevented. In this view, 
success is less about pure numbers distributed than about the 
quality of the targeting. Others describe success as “widespread, 
sustainable uptake and use of female condoms.”24 In this version 
of success, the goal is to “normalize [the female condom] as a 
potential method for all sexually active women and men, not 
just those who engage in high-risk behaviors or are living with 
HIV or AIDS.”25 Finally, some advocates of the female condom 
promote its ability to empower women to negotiate protection 
and open dialogue about sex in male-dominated societies. 
What purpose should the female condom serve today, 
against a backdrop of other prevention interventions such 
as the male condom, voluntary counseling and testing, and 
male circumcision? Three issues, presented below, must be 
examined in order to articulate a definition of success for the 
female condom: 
1. The incremental benefits of the female condom compared  
 with the male condom
2. The cost-effectiveness of the female condom compared with  
 other interventions
3. Women’s empowerment benefits from female condom use 
21 Current commodity costs of  the FC2 are an estimated $0.57, making the product 19 times as expensive as the male condom.
22 Frost, L, and Pratt, B. 2006. “A Technology for Dual Protection against Sexually Transmitted Infections and Pregnancy.” Access Book, Chapter 8-Draft. 
23 Center for Health and Gender Equity. 2008. “Saving Lives Now: Female Condoms and the Role of  U.S. Foreign Aid.” Takoma Park, MD: Center for Health and   
 Gender Equity. Note: While USAID headquarters queries missions globally on an annual basis on country needs for female condoms, requests from in-country  
 missions for female condom procurement are dependent on USAID or PEPFAR officials having experience with and knowledge about the acceptability and   
 efficacy of  female condoms. Unless a Health, Nutrition and Population Officer (representing USAID) or the Ambassador requests the female condom, there will 
  be no push from Washington, DC, to make procurement and programmatic funding available for the female condom. Further, female condoms are not  
 mentioned in the OGAC’s program guidance. In several of  the US governments’ centrally funded HIV/AIDS programs such as AIDSTAR (AIDS Support,  
 Technical Assistance Resources), female condoms are not part of  an institutional set of  services; rather, female condom program dollars must be requested   
 through individual country champions.
24 Global Campaign for Microbicides and the UNAIDS Global Coalition for Woman and AIDS. 2004. “Observations and Outcomes from the Experts’ Meeting on   
 Female Condoms.” London, 10 December. 
25 Hoffman, S, Mantell, J, Exner, T, Stein, Z. 2004. “The Future of  the Female Condom,” International Family Planning Perspectives, 30(3) 139-145.
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First, a definition of success must consider the comparative 
benefits of the female condom vis-à-vis other products that 
have broad reach and similar efficacy, such as the male condom. 
While upwards of 140 million female condoms have been 
distributed, approximately 11 billion male condoms were 
distributed worldwide in 2007 alone — and the current market 
for male condoms is still growing in many developing countries. 
For example, PSI’s male condom sales have increased from an 
estimated 340 million units in 1997 to 1 billion units in 2006. 
Furthermore, PSI has achieved significant male condom sales 
in countries with high HIV prevalence, such as Mozambique, 
Lesotho, Zimbabwe, Botswana, South Africa, and Zambia, as 
seen in Table 3.26 
It is within this context that one needs to understand the 
incremental benefits provided by the female condom, measured 
by additional cases of HIV/AIDS averted. Studies mentioned in 
this paper suggest that introduction of the female condom can 
create incremental benefits, particularly by preventing infections 
among vulnerable groups that cannot use male condoms. If 
incremental benefits are to be pursued, the female condom’s role 
could be regarded as more of a specialized product in the fight 
against HIV/AIDS, rather than a widely distributed one.
Skeptics of the female condom tend to compare distribution 
figures or usage rates unfavorably with those of the male 
condom. Typically those programs that have achieved higher 
26 www.psi.org.
unit distribution of the female condom are regarded as the 
most successful, irrespective of any greater use among particular 
audiences who might be most vulnerable (such as female sex 
workers or women in stable relationships in high-prevalence 
countries) or the cost-effectiveness of female condoms versus 
other interventions. However, even relatively low distribution 
can be compelling if the target audience is identified and effort 
is focused on those women whose partners are unable or 
unwilling to use the male condom.  
But even when targeting is strong and incremental benefits are 
gained, the male condom may still garner a higher return on 
investment because of the female condom’s high commodity 
and programmatic costs. Therefore, a second dimension of 
success should consider the cost-effectiveness of the female 
condom compared with the male condom and other prevention 
interventions. A few studies have been conducted on the cost-
effectiveness of the female condom, but they have not examined 
the critical issue of cost-effectiveness compared with other HIV 
prevention alternatives, such as the male condom. David Dowdy 
and Michael Sweat modeled the expansion of the FC2 in Brazil 
and South Africa and found that distribution of the female 
condom to 10% of current male condom users would avert an 
Table 3: PSI male condom distribution in selected high HIV prevalence  
countries — 1999, 2006, and compound annual growth rate (CAGR)  
from 1999-2006
Source: PSI, FSG analysis 
1999 2006 CAGR
Mozambique 9,858,401 22,732,196 0.13
Lesotho 347,998 3,167,929 0.37
Zimbabwe 8,961,442 49,122,000 0.28
Botswana 2,744,568 4,107,377 0.06
South Africa 3,920,479 22,428,888 0.28
Zambia 6,724,646 13,208,310 0.10
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estimated 604 HIV infections at $20,683 per infection in Brazil, 
and 9,577 infections at $985 per infection in South Africa.27  
Other work in this area, a study by PATH/UNFPA, identified 
cost savings to the health care system based on a modeled 
number of new infections averted.28  
The female condom may at first seem cost-effective because 
it increases the total number of protected sexual acts, but this 
finding does not necessarily mean that the female condom 
is more cost-effective than the male condom. Such cost-
effectiveness assessments without such a comparison are 
incomplete: female condoms may increase the number of averted 
cases of HIV/AIDS, but we do not know whether the same 
number of cases could have been averted through the less costly 
support of the male condom or other prevention interventions.
Third, it is necessary to better understand the important benefits 
of women’s empowerment conferred by the female condom. 
Research has shown an “empowerment effect” from the female 
condom, which can be conferred to the individual woman or 
the health system overall. The benefits include women’s enhanced 
ability to negotiate safe sex, increased openness to discussing 
sex, and sexual pleasure and pride in their bodies.29 Female 
empowerment benefits also include the female condom’s ability 
to act as an important catalyst for more general empowerment 
and self-efficacy. Programs that distribute the female condom 
throughout the developing world strengthen programmatic 
relationships with marginalized groups, such as female sex 
workers. Kaler suggests that even if female condom uptake is 
slow or modest, the programmatic value of interpersonal or mass 
media communication that features women using this device is 
a profound boon for public health.30  
There is a need to better understand these additional benefits, 
since women’s empowerment and HIV prevention are linked. 
Women who cannot negotiate barrier protection with a partner 
who may be infected cannot reap the benefits of such protection. 
Erica Gollub canvassed the literature on the “empowerment 
effect” of the female condom and found multiple studies that 
demonstrate the female condom’s ability to increase sexual 
confidence that may “in a small way open up the possibility 
of greater equality in sexual relations between men and 
women.”31 Further, international consultations, such as the 
International Conference on Population and Development 
(Cairo, 1994), have articulated the connection between women’s 
empowerment and sexual health and declared that women’s 
empowerment is an important end in itself: “The Programme of 
Action, adopted by 179 governments, marked a new understanding 
among world bodies that population and development are 
inextricably linked, and that women’s empowerment is the key to 
both. And, for the first time, the reproductive and sexual health 
and rights of women became a central element in an international 
agreement on population and development.” 32   
These views — about the size of the intended audience, the costs 
of the product itself and associated distribution costs, and the 
fact that the female condom is used by women who often do not 
share the same sexual rights as men — are tied up in the often 
emotional, complicated, and inconsistent definition of success 
of the female condom. An inconsistent definition of success for 
the female condom exposes two risks. First, at the global level, 
advocates and donors could end up talking past each other. 
Efforts to bolster the female condom (through mainstreaming 
and scale-up or through subsidization of new developers or 
manufacturers) should be reviewed to determine whether they 
are the best ways to support a relatively expensive product that 
has profound value but target-specific application. Second, at the 
country level, female condom programs may not avert significant 
numbers of HIV/AIDS cases or create desired empowerment 
benefits for the people who need them the most. In other 
words, without a consistent view of success and the funding  
and programming to support clear objectives, stakeholders 
may miss opportunities to save lives through the use of this 
important commodity.
In order to shed further light on the female condom’s role in 
prevention programs, its cost-effectiveness compared to other 
prevention interventions, and the value of female empowerment, 
we undertook the first-ever marginal cost-effectiveness modeling 
exercise comparing the female condom with the male condom.   
 
27 Dowdy, DW, Sweat, MD, and Holgrave, DR. 2006. “Country-wide Distribution of  the Nitrile Female Condom (FC2) in Brazil and South Africa: A Cost-Effectiveness  
 Analysis.” AIDS. 20:2091-98.
28 PATH, UNFPA. 2006. “Female Condom: A Powerful Tool for Protection.” Seattle: UNFPA, PATH.
29 Gollub, EL. 2000. “The Female Condom: Tool for Women’s Empowerment,” American Journal of  Public Health, 90(9): 1377-1381. 
30 Kaler, A. “The Future of  Female-Controlled Barrier Methods for HIV Prevention: Female Condoms and Lessons Learned.” Culture, Health & Sexuality, 6(6): 501–6.
31 Gollub, EL. 2000. “The Female Condom: Tool for Women’s Empowerment.” American Journal of  Public Health. 90(9): 1377-1381.
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IV. COST-EFFECTIVENESS    
 ANALYSIS
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The cost-effectiveness analysis was conducted to understand 
under what conditions the female condom could be cost-
effective when compared to the male condom. Because the 
commodity cost of the female condom is many multiples 
greater than that of the male condom, it might seem that 
the female condom would never be comparatively cost-
effective. However, there may be circumstances in which the 
male condom cannot be used or where the cost of promoting 
additional use becomes excessive. The modeling exercise 
sought to identify the conditions under which the female 
condom could be cost-effective.
IV.  Cost-Ef fect iveness Analysis
The analysis was carried out with a computer-based 
simulation incorporating key features of female condom 
use, male condom use, and program implementation. The 
analysis pays particular attention to assessing the effect of 
male condom use levels on the cost of distributing the next 
additional male condom (that is, the marginal cost) allowing 
us to compare the costs of more male condoms to the cost 
of more female condoms. Other important parameters 
include substitution effects (the rate at which couples use 
female condoms in sex episodes where male condoms 
would have been used instead), different types of marketing 
and promotion programs, male condom waste rates, and 
different types of sexual partnerships. 
As HIV prevention efforts expand, the urgency of understanding the cost-effectiveness of available prevention options 
will increase. This urgency is driven by the imperative to make the best use of available resources. Because HIV cases that 
would have occurred without prevention programs typically cannot be observed directly, computer-based epidemiologic 
and cost-effectiveness models are needed to project the consequences of new spending on prevention. Two previously 
published analyses of female condom cost-effectiveness suggested more favorable results than those advanced in the 
current study. Critiques of these studies follow: 
Dowdy, DW, Sweat, MD, Holtgrave, DR. 2006. “Country-wide distribution of the Nitrile Female Condom (FC2) in Brazil and South 
Africa: A Cost-Effectiveness Analysis.” AIDS. 20(16):2091-8.
Dowdy et al. found that the FC2 could be cost-effective in both South Africa and Brazil, where the modeled cost per 
HIV	infection	averted	is	compared	with	the	cost	of	antiretroviral	therapy	(ART).	The	appropriate	comparison	is	with	
other prevention options such as male condoms, not with treatment. The analysis also assumes that the FC2 would be 
distributed at volumes approximating 10% of male condom volumes. At higher volumes, costs decrease substantially and 
cost-effectiveness rises. These favorable results depend on the comparison of female condoms with relatively expensive 
ART	($208	and	$2,500	per	person	per	year	in	South	Africa	and	Brazil,	respectively)	rather	than	with	other	prevention	
options, especially the male condom. The study’s favorable results also stem from low female condom costs, unrealistically 
low substitution rates, and decreasing marginal costs over very large increases in distribution (i.e., not allowing for 
potential increasing need for marketing and its attendant costs).
Marseille, E, Kahn, JG, Billinghurst, K, Saba, J. 2001. “Cost-Effectiveness of the Female Condom in Preventing HIV and STIs in 
Commercial Sex Workers in Rural South Africa.” Social Sciences & Medicine. 52(1):135-48.
Marseille et al. estimated the cost-effectiveness of the female condom in the context of a hypothetical sex worker peer 
outreach program in a very high-prevalence district of South Africa. The favorable cost-effectiveness estimates of this 
study stem from an unrealistically low estimate of substitution rates, low program costs, and an estimate of the per-
episode risk of HIV transmission that was higher than estimates published later based on more sophisticated methods.  
Review of Past Female Condom Cost-Effectiveness Analyses
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We modeled and report on five types of cost and cost-
effectiveness outcomes:
1. Health outcomes. Cases of HIV averted by the   
 female condom program.
2. Fully-loaded female condom program costs.  
 These costs equal the bulk purchase price of the   
 female condoms themselves (the “commodity cost”)  
 plus packaging, distribution, education, and 
 promotion costs. 
3. Cost per incremental episode protected (IEP).  
 In evaluating the female condom versus the male   
 condom for each risk group of interest, it is sufficient  
 to establish the relative cost of protecting the episodes  
 that otherwise would have gone unprotected. 
4. Cost per HIV infection averted. This consists of net  
 program costs divided by the number of HIV cases  
 averted. From program costs, we deduct the saved  
 medical care costs from unwanted pregnancies and  
 lifetime antiretroviral costs that would have occurred  
 had the female condom not prevented pregnancies that  
 resulted in the birth of an HIV-infected child.
5. Cost per disability-adjusted life-years (DALYs) averted.  
 We repeat the above comparisons using the DALY, which  
 includes HIV and contraceptive benefits in the same  
 metric and allows comparisons between female condom  
 initiatives and other HIV or non-HIV-related public  
 health interventions. We also include DALYs gained  
 because of reduced maternal mortality associated with  
 newly contracepted episodes through use of the  
 female condom.
The term “fully-loaded cost” refers to all of the costs entailed in delivering condoms to their users. In addition to the commodity 
itself, these costs include packaging, shipping, and storage; transportation to the point of sale; and marketing, promotion training, 
and overhead costs. 
The “average fully-loaded cost” consists of the sum of these costs divided by the number of condoms sold.  The term “marginal 
cost” refers to the cost of distributing just one more condom package. Marginal cost may be either higher or lower than average 
costs.	Because	many	of	the	components	of	a	condom	program	are	fixed	in	the	short	run,	(e.g.,	rent,	administrative	overhead,	
capital equipment), marginal costs may be lower than average costs. For example, rent does not increase if one more package 
of	condoms	is	sold.	However,	as	the	market	for	condoms	is	satisfied,	it	requires	more	resources	to	identify	and	reach	the	next	
potential condom user. This tends to make marginal costs higher than average costs.  
 
Average Costs and Marginal Costs
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 33 Marseille, E, Kahn, JG, Billinghurst, K, Saba, J. 2001. “Cost-effectiveness of  the Female Condom in Preventing HIV and STDs in Commercial Sex Workers in Rural  
 South Africa.” Social Science & Medicine. 52(1): 135-48.
Cost-effectiveness	is	relative,	and	nothing	is	intrinsically	cost-effective.	Rather,	cost-effectiveness	analyses	indicate	whether	
one	use	of	funds	is	likely	to	generate	more	benefit	than	the	same	funds	directed	to	some	other	use.		Thus,	all	cost-
effectiveness analyses should be explicit about what options are being compared.
The current analysis focuses on female condom cost-effectiveness compared with that of the male condom. It then expands 
the set of comparators to consider a broader set of HIV prevention options. The male condom is the most appropriate 
initial comparator to the female condom because both products are barrier protection methods and agencies that are 
organized to promote one type of condom are well positioned to promote the other, and indeed many promote both.
However, we recognize that the male condom has an advantage over the female condom in that it has been marketed 
aggressively and has been ubiquitous in the developing world for the last 30 years, whereas the female condom is still 
an immature product in many developing countries. A generation of men and women has grown up aware of the male 
condom as a tool to avert pregnancies or STIs. Women are only beginning to learn about the female condom and many  
do so without the attendant sexual freedom enjoyed by men. If female condom uptake increases, unit costs could decline. 
We explore the implications of lower female condom costs on cost-effectiveness results.
Cost-effective Compared with What?
The analysis incorporates setting-specific cost, price, 
condom market, and epidemiological data, and model 
parameter estimates drawn from peer-reviewed scientific 
literature wherever possible. Program costs in this model 
were based on the social marketing programs of Population 
Services International (PSI). PSI is one of the largest 
implementers of female condom programs in the world, 
with active programs in 20 countries. We used PSI’s female 
condom cost data because of the quality and availability of the 
information and the consistency of its reporting formats across 
countries and years. However, we also explore the implications 
for the cost-effectiveness of providing free female condoms in 
the context of public sector programs. Results were subjected 
to extensive sensitivity analyses, including univariate, scenario, 
and threshold analyses. We analyzed the costs and benefits of 
the earlier version of the female condom, the FC1. The most 
recent version of the female condom is the FC2, made of 
synthetic latex. The FC2 costs about $0.30 less to manufacture 
than the FC1 and appears to have similar benefits and possibly 
higher levels of acceptability. Should the FC2 prove successful, 
it is likely to have a more favorable cost-effectiveness profile. 
However, the lower cost of the FC2 would not change the 
major direction of our findings.  
Please note: For those interested in more detail on the  
cost-effectiveness analysis, a separate article describing the technical 
specifics is forthcoming.
Finally, we did not include the female condom’s benefits in 
reducing other STIs, such as syphilis and gonorrhea. The male 
condom has equivalent benefits in this regard; therefore, STI-
related benefits would be neutralized in that key comparison. 
Furthermore, compared with combined HIV and contraceptive 
benefits, the STI-related benefits are modest.33  
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34 Pinkerton, SD, Abramson, PR. 1997. “Effectiveness of  Condoms in Preventing HIV Transmission.” Social Science & Medicine. 44(9):1303-12.
35 Trussell, J, Sturgen, K, Strickler, J, Dominik, R. 1994. “Comparative Contraceptive Efficacy of  the Female Condom and Other Barrier Methods.” 
 Family Planning Perspectives. 26(2):66-72.
36 Elias, CJ, Coggins, C. 1996. “Female-controlled Methods to Prevent Sexual Transmission of  HIV.” AIDS. 10 Suppl 3:S43-51.
37 Fontanet, AL, Saba, J, Chandelying, V, et al. 1998. “Protection Against Sexually Transmitted Diseases by Granting Sex Workers in Thailand the Choice 
 of  Using Male or Female Condoms: Results from a Randomized Controlled Trial.” AIDS. 12(14), 1851-9.
38 Thomsen, SC, Ombidi, W, Toroitich-Ruto, C, et al. 2006. “A Prospective Study Assessing the Effects of  Introducing the Female Condom in a Sex Worker  
 Population in Mombasa, Kenya.” Sexually Transmitted Infections. 82(5):397-402.
39 Musaba, E, Morrison, CS, Sunkutu, MR, Wong, EL. 1998. “Long-term Use of  the Female Condom among Couples at High risk of  Human Immunodeficiency  
 Virus Infection in Zambia.” Sexually Transmitted Diseases. 25(5):260-4.
40 Hoke, TH, et al. “Temporal Trends in STI Prevalence and Condom Use Following Introduction of  the Female Condom to Madagascar Sex Workers”    
41 Ministry of  Health, Brazil. 2000. “Acceptability of  FC in Different Social Contexts,” Brasilia.
42 Choi, KH, Gregorich, SE, Anderson, K, Grinstead, O, Gomez, CA. 2003. “Patterns and Predictors of  Female Condom Use among Ethnically Diverse Women  
 Attending Family Planning Clinics.” Sexually Transmitted Diseases. 30(1):91-8. 
43 Myer, L, Mathews, C, Little, F (2001). “Tracing Condom Fates: Design and Pilot Results of  a Study Investigating the Use and Wastage of  Public Sector Condoms.”  
 African Journal of  Reproductive Health / La Revue Africaine de la Santé Reproductive. 5:66-74.
44 Myer, L, Mathews, C, Little, F, Karim, SS. 2001. “The Fate of  Free Male Condoms Distributed to the Public in South Africa.” AIDS. 15(6):789-93.
45 Because access to female condoms is often limited and re-use has been reported, WHO commissioned two consultations to study the evidence on the issue.   
 Based on the findings, WHO does not recommend or promote re-use of  female condoms. Sources: Laura Frost. 2002. “WHO Information Update: Considerations  
 regarding Re-use of  the Female Condom, July 2002.”
 derive estimates of female-condom-to-male-condom  
 substitution rates. These estimates are included in the  
 model.37, 38, 39, 40, 41, 42 In all of these studies the female  
 condom was distributed free of cost. Basic economic 
 theory suggests that if they were priced, and especially 
 if they had a higher price than the male condom,  
 substitution rates would decline. Female condom 
 purchase and use levels would also decline.
• Male condom and female condom waste rates.   
 The model incorporates the best available data on the  
 portion of male condoms that are distributed but never  
 used.43, 44  While the waste rate for female condoms must 
 be greater than zero, in the absence of pertinent data, we  
 assume that there is no female condom waste, thus biasing  
 results somewhat in favor of the female condom. 
• Female condom re-use. It is possible to wash and 
 re-use the female condom, although studies indicate that  
 this rarely occurs in practice. The model assumes no re-use  
 of the female condom. Re-use for newer versions of the 
 female condom (FC2 or the Dr. Reddy’s female condom)  
 may be even less likely or not recommended.45 
• Perinatal and infant HIV medical cost savings. 
 The female condom is as effective as the male condom 
 in preventing pregnancy. Perinatal cost savings are thus  
 immaterial in a comparison of the effectiveness or 
 cost-effectiveness of these two barrier methods. However,  
 when comparing the female condom with other HIV 
 prevention interventions that have a lower contraceptive  
 benefit, the excess benefit of the female condom in   
 reducing perinatal and infant HIV medical costs must  
 be taken into account. Our estimate accounts for the  
A. Model Input Parameters 
The model assumes equal effectiveness in male and female 
condoms.34, 35, 36 Six key inputs underpin the model: 
• HIV transmission rates. The model incorporates the  
 best available estimates on the risk of transmission per  
 episode of unprotected sex.
• Female condom and male condom costs. Fully loaded  
 unit costs for 12 PSI male and female condom   
 programs are shown in Table 4. The non-commodity  
 portion of  female condom distribution tends to be about  
 the same as for male condom distribution, or 60 to 65%.  
 The fully loaded cost of the male condom declines as  
 volume increases and fixed costs are spread over more units  
 and levels off. It then rises as it becomes more expensive to  
 reach the last portion of potential male condom users and  
 episodes. The marginal cost of the female condom also  
 changes with coverage levels. However, lacking 
 sufficient data to fully quantify this effect, we used 
 average female condom costs as calculated by PSI.  
 We have also documented results based on country- 
 specific data gathered as part of this study from Tanzania,  
 Zambia, Zimbabwe, and Myanmar that better reflect  
 marginal costs than the unit costs presented in Table 4. 
• Substitution of female condoms for male condoms.  
 A certain portion of female condoms will actually  
 displace male condoms. As the proportion of episodes  
 covered by male condoms rises, more are susceptible 
 to this “substitution” effect. This effect is supported 
 by data from six studies, from which we were able to 
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46 In addition, we estimated the life-years added through reduced maternal deaths resulting from episodes newly contracepted via the female condom, 
 and added these to the averted DALYs resulting from female condom availability.
Loaded Unit Costs
Percent CPG  
of  Total Program Cost
Non-COG 
 Program Costs
MC FC MC FC MC FC
Cameroon
Congo
Mozambique
South Africa
Tanzania
Togo
Zambia
Zimbabwe
India
Myanmar
Thailand
Haiti
$0.10
$0.11
$0.23
$0.14
$0.10
$0.21
$0.21
$0.09
$0.11
$0.08
$0.13
$0.10
$1.37
$1.74
$3.38
$1.79
$2.00
$2.34
$1.81
$1.47
$2.35
$3.12
N/A
$1.38
38.2%
54.5%
16.9%
32.0%
31.4%
56.2%
33.4%
59.3%
39.5%
54.3%
36.6%
33.1%
52.9%
36.3%
19.2%
36.4%
37.1%
31.5%
41.4%
46.7%
29.8%
22.8%
N/A
46.3%
61.8%
45.5%
83.1%
68.0%
68.6%
43.8%
66.6%
40.7%
60.5%
45.7%
63.4%
66.9%
47.1%
63.7%
80.8%
63.6%
62.9%
68.5%
58.6%
53.3%
70.2%
77.2%
N/A
53.7%
Average over countries $0.13 $2.07 40.4% 36.4% 59.6% 63.6%
Averaged over up to 9 years of PSI program; at PSI program level of coverage; usually > 50% of episodes.
Total program costs divided by sales.
“Cost of goods” is commodity and packaging costs.
Table 4: Country-specific averages for fully-loaded male condom  
and female condom costs
Source: Population Services International (PSI) data
 probability of pregnancy, the portion of pregnancies that  
 go to term, the proportion of births that are unwanted  
 as opposed to mis-timed, the cost of perinatal care  
 including postnatal family planning services, and the  
 portion of the population that has access to PMTCT  
 services and ongoing antiretroviral drug therapy. The  
 average cost of a pregnancy is based on the relevant  
 portions of the WHO-recommended mother-baby  
 package. Because contraception reduces the incidence of  
 mother-to-child HIV transmission, in places where there 
 is access to antiretroviral therapy this means saving a  
 lifetime of treatment costs, which thereby enhances the  
 cost-effectiveness of the female condom. Pregnancy-related  
 costs averted are about $0.10 per newly protected episode  
 and averted HIV costs are an additional $0.13 per newly  
 protected episode.46  
We employed multiple sensitivity-analysis techniques to model 
and assess how results change with a wide range of changes 
in the values of key inputs. These analyses were particularly 
important in this study because not all of the data were available 
in optimal form. We conducted one-way sensitivity analyses 
in which the values of key variables were altered one at a time, 
as well as scenario sensitivity analyses in which multiple inputs 
were changed to simulate a different setting or implementation 
scenario.
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B. User Groups
The market for female condoms consists of users with widely 
varying sexual behavior and HIV prevalence and susceptibility 
profiles. These factors affect both the cost and the effectiveness 
sides of the economic assessment. In order to portray this 
variation and to ensure that the analysis captures the most 
feasible cost-effective strategies, we constructed three user or 
client-type scenarios for the female condom. We then applied 
these scenarios in a high-prevalence setting that would support 
a more favorable cost-effectiveness outcome than would lower 
prevalence settings. 
The three user groups or client-type scenarios we portray  
are FSWs, women with regular partners, and women with 
casual partners.
• Female sex workers. FSWs and their clients are   
 portrayed in our model as having a very high risk of HIV  
 infection. Given typically high male condom usage  
 rates among sex workers, the model assumes high rates of  
 substitution of male condoms with female condoms within  
 this population group. Because the prevalence of HIV  
 is high in sex workers and their clients, the frequency of  
 discordant episodes is also high.47 
 • Women with regular partners. This scenario portrays  
 female condom users whose sexual relationships   
 are overwhelmingly with spouses or with other “steady”  
 partners. Male condom use tends to be low in these  
 partnerships, and substitution rates are also low. Although  
 in high-prevalence settings women with steady partners  
 are still highly vulnerable, HIV prevalence rates tend to be  
 relatively lower in this scenario, as are discordance rates.  
 Since a high proportion of women are in regular 
 partnerships, the lower annual risk levels in regular   
 partnerships are consistent with recent findings that  
 discordant regular partnerships account for a very high  
 proportion of total incidence.48  That is, annual risk can 
 be lower in regular than in casual partnerships, yet still  
 account for a larger portion of total incidence.
• Single women. These female condom users primarily  
 have sex with casual partners. Male condom use levels,  
 substitution, HIV prevalence, and discordance all assume  
 values that are somewhat higher than in the “women with  
 regular partners” scenario and lower than in the sex worker  
 scenario.
C. Key Findings
Female condoms appear to be much less cost-effective than male 
condoms when distributed through traditional social marketing 
and public sector channels. Table 5 displays the central results 
from our study. Results are presented as the ratio of costs per 
newly protected episode between the female condom and the 
male condom. On the bottom two rows of Table 5 we show 
the cost of the female condom per HIV case averted and per 
disability-adjusted life-years averted. Since a number of viable 
HIV prevention options have cost-effectiveness ratios of $100 
per DALY averted or better and less than $500 per HIV case 
averted, it would appear that the female condom is not cost-
effective, even with this expanded range of comparators. 
Table 5: Summary cost-effectiveness results with traditional condom  
social marketing
Source: Cost-effectiveness model
SWs Women with regular partners Single women
MC cost per added episode protected
FC cost per added episode protected
$0.50
$10.90
$0.10
$2.20
$0.20
$2.40
Ratio	of	FC	:	MC	cost	per	episode	protected 21 15 13
Ratio	of	FC	:	MC	cost	per	episode	protected	
if ignore substitution
4 14 11
Cost per HIV infection averted 
Cost per DALY averted
$20,640
$1,020
$9,800
$480
$8,450
$420
47 “Discordance” refers to sexual episodes between an infected and an uninfected person, the only type in which HIV transmission can occur and therefore the   
 only type in which either the female condom or the male condom can be effective. All else being equal, the higher the level of  discordance, the greater the  
 likelihood any given condom will interrupt HIV transmission.
48 Dunkle, KL, Stephenson, R, Karita, E, et al. 2008. “New Heterosexually Transmitted HIV Infections in Married or Cohabiting Couples in Urban Zambia and   
 Rwanda: An Analysis of  Survey and Clinical Data.” Lancet. 371(9631):  2183-91.
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The precision of this analysis was constrained by absent or 
imperfect data on a number of important input parameters. 
Perhaps the most important limitation stems from a dearth of 
information on how the unit cost of male and female condoms 
varies by sales volume. As mentioned under “female condom and 
male condom costs” previously, we have extensive information 
on average unit costs. However, we have limited marginal cost 
data for programs that include male condom promotion and 
other prevention activities. Apart from Zimbabwe, we also have 
no information about the cost of attaining new episodes of 
protection within an existing male condom promotion program. 
The marginal cost of the male condom could be lower than 
the average costs, as we found for the female condom. This is 
because	as	fixed	costs	are	spread	across	a	larger	number	of	
condoms, average costs decline. However, as male condom use 
increases, programs may need to increase their expenditures on 
promotion, suggesting an increase in marginal costs. We make 
the assumption, favorable to cost-effectiveness for the female 
condom, that male condom marginal costs are rising. This is 
“favorable” in the sense that, compared with the male condom, 
the female condom looks increasingly cost-effective as male 
condom costs increase. However, there may be situations in 
which male condom costs are so high that the male condoms 
are no longer cost-effective. At that point, the proper standard by 
which to measure female condom cost-effectiveness would no 
longer be the male condom, but other types of readily available 
prevention strategies.
Similarly, there are no data on how the marginal costs of the 
female condom change with program expansion. At a certain 
point, those who are easiest to reach will have been reached, and 
the cost of distribution begins to rise, thus increasing unit costs. 
Our analysis does not account for these eventual rising costs and 
instead uses current average cost and marginal costs based on 
current sales volumes.
Our estimates of substitution rates are based on six published 
studies that document male condom coverage levels before 
and after the introduction of the female condom. They range in 
male condom coverage from 31% to 97% of episodes. Client 
groups include sex workers, family planning patients, and STI 
clinic	patients.	The	data	show	a	strong	correlation	and	close	fit	
between male condom coverage and substitution. However, 
because substitution affects cost-effectiveness, particularly in 
groups with high substitution such as sex workers, it would 
be useful to gather more information on substitution levels by 
particular user groups. Imposing a higher price on the female 
condom than for the male condom should also have the effect of 
lowering	substitution,	and	these	price	effects	should	be	quantified.
Because of an absence of data, we were also not able to analyze 
the marginal costs of the male condom and the female condom 
Data Limitations of this Study
by user group, such as regular partnerships, sex workers, and 
their clients. It is likely that marketing and distribution costs for 
some	of	these	groups	diverge	significantly	from	average	program	
unit cost. The analysis would allow for cost-effectiveness results 
that	more	accurately	reflect	the	costs	of	attaining	increased	use	
levels among the various female condom users.
We also found limited usable data pertaining to the portion of 
male condoms that are wasted. Importantly, all of the information 
on condom waste pertains to free condom programs where 
one would expect waste levels to be higher. Based on a study of 
free, publicly distributed condoms in South Africa, which indicated 
a 13% waste rate, we adopted 20%, 10%, and 5% rates of waste  
by FSWs, women in casual partnerships, and women in regular 
partnerships, respectively. (Myer, L., et al., The fate of free male 
condoms distributed to the public in South Africa. Aids, 2001. 
15(6): p. 789-93.)
The	estimates	derived	for	the	contraceptive	benefits	of	the	
female condom also contain parameters for which data are 
sparse. For example, we do not know with certainty what 
portion of births was truly unwanted as opposed to being  
mis-timed in HIV-negative versus HIV-positive mothers. Nor 
are good estimates available for the pregnancy reduction 
benefits	of	other	HIV	prevention	interventions	against	which	
female condom cost-effectiveness might be compared, such 
as voluntary counseling and testing; information, education, and 
communications campaigns; and school-based interventions. 
These interventions can reduce unprotected episodes through 
partner and episode reduction and thus also reduce the risk  
of pregnancy.
Finally, derivations of demand curves for both male and female 
condoms are also excluded from our analysis. Demand curves 
quantify and display how condom consumption varies with price. 
These curves, if available, would help us predict the effect of using 
price as a tool for reducing the rate at which female condoms 
substitute for male condoms. The data available on how price 
variation within a country affects demand are sparse, with very 
limited price variation. Further, the demand data are aggregated, 
so we cannot separate the effect of price on the number of 
users from the level of use among users. This distinction may 
have implications for unit costs. Nevertheless, we are able to 
relate fully-loaded unit costs of condoms to individual use levels 
in	each	country.	This	information	is	sufficient	to	derive	the	
cost-effectiveness estimates expressed as the cost per newly 
protected episode. Where data were absent or incomplete, we 
ran sensitivity analyses with a wide range of plausible inputs for 
key inputs and combinations of inputs. The sensitivity analyses 
suggest	that	our	qualitative	findings	—	that	the	female	condom	
is substantially less economically attractive than the male condom 
and	other	HIV	prevention	options	—	are	true	for	the	majority	of	
plausible combinations of input values.
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In	settings	where	there	is	a	significant	unmet	demand	for	male	condoms,	it	makes	sense	to	scale	up	access	to	male	condoms	
before	large-scale	introduction	of	the	female	condom.	This	is	because	it	is	more	efficient	to	cover	risky	sex	episodes	with	relatively	
inexpensive male condoms than with more costly female condoms wherever possible. However, what about settings with a 
long history of intensive male condom marketing? Are at least some of these markets “saturated”? That is, have some markets 
reached a point in which everyone who can be persuaded to use male condoms is in fact using them? Might some of the residual 
unprotected sex then be “topped off” with the introduction of the female condom? There are three reasons to believe that a focus 
on “saturated markets” is unlikely to yield a cost-effective role for the female condom:
• First, broadly speaking, the market for male condoms is far from saturated as evidenced by the rising demand for male 
	 condoms	in	many	developing	countries.	As	noted	above,	it	is	more	efficient	to	address	existing	unmet	demand	with	male 
	 condoms	than	with	female	condoms	because	of	the	significant	cost	differential.
• Second, it is not easy to know when a market is saturated. What constitutes a fully rigorous promotion campaign?  
 Effective demand can change both because of program marketing activities and because of secular trends. The 100%  
 Jeune campaign of Population Services International in Cameroon provides a good example of the role of both of these   
	 variables	in	affecting	male	condom	uptake.	(Plautz,	A,	Meekers,	D.	2007.		“Evaluation	of	the	Reach	and	Impact	of	the	100% 
 Jeune Youth Social Marketing Program in Cameroon: Findings from Three Cross-Sectional Surveys.” Reproductive Health. (4)1.) 
• Third, topping off the residual unprotected episodes without any particular target audience in mind could result in many of  
 the female condoms simply displacing male condoms. 
Male Condom “Saturation” and Female Condom Cost-Effectiveness
The numerical results summarized in Table 5 suggest a fairly 
dramatic difference in the cost-effectiveness of the female 
condom as compared to the male condom — specifically, the 
cost of the female condom is estimated to be roughly 13 to 21 
times higher than that of the male condom. Sensitivity analysis 
using FC2 costs rather than FC1 costs improves the cost-
effectiveness, but not by much: the female condom drops to 
being 10 to 20 times higher in cost than the male condom.
Perhaps the most surprising result of this analysis is that 
traditional female condom programs are not cost-effective even 
for female sex workers who are at very high risk. This is because 
substitution rates (of female condoms for male condoms) are 
very high in this group, so that only a small portion of female 
condoms provides additional protection. For women with 
regular partners, female condoms are not cost-effective because 
of the lower cost of the male condom compared with the female 
condom and because HIV risk levels are generally lower in 
women with regular partners than in sex workers and in many 
women with primarily casual partners. (Relatively lower risk 
levels are still consistent with the fact that women in regular 
partnerships account for a high portion of total incidence.) 
For single women, cost-effectiveness of the female condom is 
compromised by both significant substitution and the large cost 
differential between female condoms and male condoms. The 
factors unfavorable to female condoms overwhelm the effect of 
the modestly higher risks in this group compared with women 
who have regular partners.
It should be noted that in some settings and in some female 
condom user groups, particularly women with regular partners, 
the estimates of male condom marginal cost used in the 
model may be too low. Men may not use the male condom, 
regardless of the intensity and quality of condom marketing 
and information campaigns. In these situations, the correct 
comparison is no longer between female condoms and male 
condoms. Because male condoms are not an option, female 
condoms should be compared with other possible HIV 
prevention options. This reasoning can be applied to any 
situation in which the market for male condoms is “saturated” 
— that is, where every reasonable effort has been made to 
generate demand and to fulfill that demand. After a certain level 
of male condom adoption, the cost of further adoption becomes 
exorbitant, and male condoms are no longer a reasonable 
comparator. However, with a range of $400 to $1,000 per 
DALY averted, the female condom is not an attractive option 
when compared with the best available data on the cost-
effectiveness of other underutilized HIV prevention strategies, 
such as male circumcision, FSW outreach and counseling 
programs, or prevention of mother-to-child-transmission. 
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Assuming that reducing HIV transmission is a primary program 
goal, the female condom may not be a cost-effective alternative, 
even where it is impossible to increase male condom uptake.
 
There are combinations of parameter values in which the 
female condom could be cost-effective compared with the 
male condom. This occurs whenever the fully loaded marginal 
cost of the male condom exceeds that of the female condom 
and substitution levels are under about 10%. However, in 
order for either condom to be cost-effective compared with 
other available HIV prevention options, the unit cost would 
need to be under about $1.50, and used in discordant pairings 
about 25% of the time. This implies HIV prevalence of about 
15% or higher. As will be described in the Conclusions and 
Recommendations sections, the combinations of conditions 
under which the female condom might be cost-effective are 
likely to be limited. 
Lastly, the analysis attempted to calculate the opportunity costs 
of the female condom in terms of the empowerment benefits 
that have been studied and were discussed earlier. No data 
exists on the value of these empowerment benefits at present. 
We addressed this issue by a simple thought experiment of 
quantifying the value that would have to be placed on these 
benefits in order for the female condom to become cost-
effective. In an exploratory scenario, to avert 100 cases of HIV, 
a significant amount of funds — ranging between $400,000 
to $900,000 — would have to be spent on the female condom 
over what would have to be spent on the male condom. To put 
this another way, with a budget of $100,000, between 90 and 
120 additional cases of HIV could be averted by investing in the 
male condom rather than the female condom. These estimates 
prompt us to ask whether the non-HIV prevention goals of 
the female condom could be achieved more efficiently through 
other means. 
D. Findings Discussion
The results presented in Table 5 are based on average condom 
cost figures and typical HIV prevalence rates in sub-Saharan 
African countries. However, there are scenarios where the female 
condom will fare much better or worse, depending on female 
condom costs, male condom costs, different substitution rates, 
and HIV prevalence. For example, in South Africa, a country 
with high HIV prevalence, fairly low female condom costs, and 
roughly average male condom costs, the cost-effectiveness of the 
female condom would be better than for any of the user groups 
shown in Table 5. Depending on the particular user group and 
the substitution rates, the cost-effectiveness could improve even 
further (or worsen).
 
Much depends on what happens in any particular country and 
with any particular user group as managed within a particular 
program. The modeling exercise shows a vast difference in 
cost-effectiveness between male and female condoms based on 
average costs. It may be difficult or impossible to close this gap, 
but it can be narrowed through attention to a number of key 
levers. These levers are discussed below. 
 
1. Substitution rates: Based on the cost-effectiveness   
 modeling work conducted, substitution rates seem to  
 be relatively low for women in long-term relationships.  
 For FSWs, substitution is high overall, with a minority  
 of  “low substitution” sex acts where use of the male  
 condom may not be possible. Assigning a higher price 
 to the female condom compared with the male condom 
 should reduce the substitution of female condoms. 
 However, we found that shifting a program from priced 
 female condoms to free female condoms has a very 
 unfavorable effect on incremental cost-effectiveness, 
 because of the high rates of substitution among those  
 newly recruited to the female condom.   
2. Use of the female condom by known discordant   
 partners increases both incremental cases of HIV averted  
 and cost-effectiveness, because only in such pairings is there  
 a risk of HIV transmission. 
3. Marginal costs of the male condom: Some target  
 audiences — for example, women in long-term   
 relationships — require high levels of investment in male  
 condom promotion to convince them and their partners  
 to use the male condom. Female condom cost-effectiveness  
 is enhanced when used by these target populations.
4. In order to increase cost-effectiveness, the marginal  
 costs of the female condom can be reduced. Cost   
 reduction options include more efficient program planning  
 and capitalizing on economies of scope by integrating  
 with and leveraging other activities, such as male condom  
 distribution, as a primary area of focus. Female condom  
 marginal costs may be particularly low in programs that  
 sponsor many activities and can therefore distribute  
 fixed costs over multiple activities (such as sharing the  
 costs of transport between female condom programs and  
 male condom programs). 
5. Any reduction in the commodity cost of the female  
 condom may improve cost-effectiveness. 
In summary, we recognize that cost-effectiveness is not the 
only criterion on which funding decisions for the female 
condom should rest. Importantly, where the female condom 
is the only technology that can be used by women to protect 
themselves, every effort must be made to ensure that women 
are protected as cost-effectively as possible through attention 
to the levers mentioned above. There are also important social 
goals supported by female condom promotion that are difficult 
to quantify. However, a very high estimate would need to be 
assigned to the female condom’s ability to help attain these  
other goals in order to justify spending on the female condom.
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As this study has shown, the female condom has been 
introduced in dozens of developing country settings, and 
during the last 15 years it has:
• Generated interest and use under tough budgetary   
 constraints 
• Averted cases of HIV and unwanted pregnancies
• Created strong voices of support for women’s individual  
 and societal sexual rights 
• Spurred new technical improvements
• Awakened governments, donors, and implementers to the  
 importance of multiple approaches to HIV prevention 
Yet, against this impressive backdrop, the female condom  
is at an impasse with key funders ambivalent about its 
future, mostly because of concerns about commodity and 
programmatic costs. The result is an unhelpful stalemate of 
sorts, with advocates calling for a “fair run” for the female 
condom and researchers and skeptical donors wanting more 
data and proof before deliberate action and investment can  
take place. This report offers a number of conclusions that can 
help to break this impasse.
1. The female condom deserves support as a vital   
 technology in the toolbox of HIV prevention when 
 it can be directed to individuals who cannot or will  
 not use the male condom. This analysis supports   
 programming for the female condom that is as   
 cost-effective as possible.
2. The field does not have a consistent definition of   
 success for the female condom. Some view the  
 female condom as a specialized product that should  
 provide incremental HIV protection, complementing  
 the male condom. Other interviewees felt that more units 
 distributed represents success regardless of whether female  
 condoms prevent new cases of HIV, or whether the  
 female condom is introduced in a cost-effective manner.  
 Some advocates view distribution of the female condom  
 as being important in conferring women’s empowerment  
 benefits both to the individual and society, and that  
 empowering women is a key step toward stemming the  
 epidemic. The lack of a consistent definition of success for  
 the female condom is probably the greatest blind spot for 
 this prevention option and the most severe obstacle to  
 garnering additional support. A definition of success for  
 the female condom is offered in “Recommendations”.
3. The female condom is currently not cost-effective.  
 The female condom is much less cost-effective than male  
 condoms when distributed through traditional social  
 marketing and public sector channels. The female   
 condom is also substantially (10- to 100-fold) less cost- 
 effective than other available HIV prevention strategies.  
 With the introduction of the FC2, commodity costs have  
 come down for the female condom, but such reductions  
 are insufficient to change the direction of our findings.  
 While cost-effectiveness is only one consideration in the  
 choice of different prevention strategies, we believe that 
 this analysis should inform the design of female condom  
 programs so that they might become more cost-effective 
 in the future.
4. The female condom provides crucial benefits   
 in terms of women’s empowerment, but these   
 are difficult to quantify. Women’s empowerment is  
 central to effective HIV prevention, and programs that 
 confer these benefits should be supported by donors.  
 However, this does not necessarily mean that the female 
 condom is the most effective or most cost-effective means  
 of delivering these benefits. Research is needed to specify  
 these benefits, such as an individual woman’s improved  
 ability to discuss and negotiate sex.    
V. Conclusions
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The various analyses conducted in this study — a literature 
review, expert interviews, research on 14 active female 
condom programs in developing countries, and a cost-
effectiveness modeling exercise — point to the paramount 
need for a consistent definition of female condom success and 
a framework for putting the definition into action. A new 
definition of success is recommended below, followed by advice 
on “smart programming.”  Lastly, additional and more specific 
recommendations are offered to program managers, donors, 
and academics.
A. A New Definition of Success for  
 the Female Condom
The female condom should provide benefits for HIV/AIDS 
prevention at a cost that compares reasonably with the 
incremental costs of alternative ways to prevent HIV, with due 
acknowledgment and understanding of the many benefits that 
do not readily lend themselves to quantification. 
A similar definition of success was broached at a technical 
update held on the female condom in 2001. However, the 
definition was limited to incremental benefits, not cost-
effectiveness relative to the male condom, and the idea of 
additional benefits was missing.49 This new definition of  
female condom success challenges the notion that more 
investment should be dedicated to the female condom solely 
because its current distribution and investment are low 
compared with that of the male condom. This definition also 
brings up the issue of additional choice in prevention methods 
as an end in itself. Donors may value choice in prevention 
options, but program managers are faced with the practical 
consequences of trading off choice against other important 
values. As long as the female condom is supported by limited 
public resources, implementers must weigh the incremental 
benefits that it can deliver — additional averted cases of 
HIV/AIDS or other benefits — against its cost. Alternatively, 
if donors value choice regardless of health benefits, the 
opportunity cost of this value should be explicitly stated. 
The proposed definition of success should rebalance the debate 
from the current dialogue on top-down, supply-oriented efforts 
to increase purchases of the female condom or reduce the 
costs of manufacturing to a greater dialogue on the bottom-
up determination of where the female condom can best 
deliver incremental value, given the relative advantages of the 
male condom. This study shows that the female condom is 
roughly 10 to 20 times more expensive than the male condom, 
depending on the target audience. This gap would be difficult 
to close through increased volumes of the female condom or 
improved manufacturing processes. Further, donor guarantee/
subsidization of higher-volume purchases and program support 
may simply duplicate benefits derived from the male condom. 
A top-down perspective is not the answer; rather, a highly 
targeted approach is more likely to achieve success as defined 
in this study.
B. Smarter Programming
The female condom should be introduced strategically to 
specific target audiences within certain countries to manifest 
the new definition of success. The UNAIDS Guide for 
Planning and Programming serves as perhaps the best guide 
at present, because it suggests that the female condom should 
be introduced as part of an integrated package of prevention 
interventions, targeted at populations that cannot use the male 
condom consistently. 
VI.  Recommendations
49 Friel, P. 2005. “Review of Past Action Plans and their Implementation.” Global Consultation on the Female Condom. Baltimore. September 26-29. (PowerPoint presentation).
The female condom should result in averted cases of HIV/AIDS and unwanted pregnancies that could not be more 
readily achieved through alternative approaches, notably additional promotion of male condoms, and should be 
distributed	in	a	manner	that	is	as	cost-effective	as	possible.	Additional	benefits,	such	as	improved	relationships	with	
marginal groups or expanded women’s rights, should be no more costly than when achieved by other interventions 
that bring about similar results.  
A New Definition For Female Condom Success In The Developing World
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But programmers can go a number of additional steps further. 
Smarter programming can improve both health impact and 
cost-effectiveness by identifying and serving target audiences 
where some combination of four critical conditions can be 
optimized: seroprevalence discordance, low substitution of 
female condoms for male condoms, low female condom 
marginal costs, and high male condom marginal costs. These 
conditions, or levers, while not necessarily new to the dialogue 
on the female condom, can be used by programmers to develop 
strategies with certain target audiences that are most likely to 
provide averted cases of HIV/AIDS not otherwise covered by 
the male condom, administered as cost-effectively as possible. 
One such strategy, which attempts to reduce the marginal 
costs of the female condom among those who are at high risk 
of infection and are not willing to use the male condom, is 
provided for illustration and discussion. 
Illustrative Strategy: The female condom as an alternative 
method of protection for female sex workers who cannot 
use the male condom. As discussed, FSWs who cannot use 
the male condom with their paying partner (because a male 
client is unwilling or cannot use one because of inebriation)  
would rank as a high priority for the female condom,  
because the product can avert new cases of HIV/AIDS in  
these risky scenarios. 
 
There are two approaches for addressing this target audience. 
First, female condom distribution can piggy-back on male 
condom campaigns — leveraging existing resources and 
infrastructure — and be positioned as an alternative for FSWs 
who cannot use the male condom. Targeting FSWs and their 
clients with male and female condom outreach would limit 
substitution. Second, the female condom can be socially 
marketed (sold) at affordable prices that are still markedly  
higher than the price of the male condom. Charging a price 
for the female condom reduces the likelihood that sex workers 
would use a female condom when a cheaper (or free) male 
condom is a possibility, but such a price might reduce female 
condom uptake.  
In assessing whether this market segment meets the criteria for 
success, program managers should weigh two additional factors. 
First, it is important to reflect upon comparative program 
investment in sex worker clients emphasizing the importance 
of male condom use. Such additional investment in male 
condom programs may not be worthwhile in countries where 
male condom use has been heavily promoted for a quarter of 
a century (most countries with significant sexual transmission 
of HIV). This may suggest that the marginal cost of the male 
condom in these circumstances would be extremely high. 
Second, program managers should consider the value of the 
less quantifiable benefits, such as markedly improved access to 
female sex worker groups (to provide other health services such 
as STI prevention, treatment, and education, etc.). 
The above strategy attempts to optimize some of the conditions 
for success. Programmers can try to find a similar scenario 
in their country settings, or they can seek out conditions of 
discordance, high marginal male condom costs, low marginal 
female condom costs, and low substitution in a range of other 
scenarios. We encourage programmers to find or create these 
conditions through sex worker outreach programs, through 
prevention-for-positives programs, by working with women in 
stable relationships, or even by working with university students. 
Without careful attention to these conditions, however, female 
condoms may not reach women most in need of them and 
they will not be delivered in a cost-effective manner. Program 
managers should be cognizant of the potential stigma conferred 
by highly-targeted programs as well. 
Additional recommendations follow for program managers, 
donors, and researchers.  
C. Stakeholder-Specific    
 Recommendations
Program Managers: Program managers have a critical role 
because they can make decisions about where and how the 
female condom is integrated into HIV/AIDS prevention 
campaigns. Specifically, program managers can consider  
the following:
• Gathering data to make more informed decisions 
about whether and how the female condom should be 
supported. The data limitations explained in this study 
could be partially remedied by improved data collection 
by program managers. Many of the 14 programs that 
FSG analyzed for this study had readily available data 
for price, staffing, and female condom distribution. 
Data was limited for costs of promotion, interpersonal 
communication, and provider training. Expenditures 
per target group were, in almost all cases, unavailable. 
Program managers could attempt to collect this 
information and calculate the true marginal costs for 
the female condom or any other intervention that uses a 
male condom program as a foundation. 
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• Evaluating their smarter programming efforts: 
 – Target audience discipline: To ensure that the  
 female condom is not being offered across the  
 board, program staff can do simple market  
 audits annually. 
 – Cost-effectiveness: A primer to help conduct a  
 rough but useful estimation of the marginal cost  
 of the female condom follows. This costing  
 exercise is likely to generate a better understanding  
 of the female condom cost structure and identify  
 opportunities to contain those costs.
 – Measurement and enhancement of incremental  
 benefits: Estimation of incremental benefits is  
 complex. A thorough assessment would require  
 estimation of the portion of condoms used in  
 formerly risky sex acts. Assessing risk, in turn,  
 requires data on the behavior profile of female  
 condom users and their partners, and on the  
 HIV prevalence level in these groups. A simpler  
 but still useful assessment might consist of a  
 survey of female condom users that generates  
 information on frequency of sex episodes and  
 prospectively assesses the portion of condom- 
 protected episodes, before and after initiation of  
 female condom use by the consumer. This survey  
 may provide actionable information that program  
 managers can use to refine the marketing and  
 targeting of the female condom.
      
1. Time frame. Select a recent period such as the last 12 months. Estimate the number of female condoms that the 
program distributed during that period.
2. Commodity costs. Assign a current unit commodity and packaging cost and multiply the unit cost by the number of 
condoms sold (or distributed for free).
3. Personnel.	For	each	staff	member,	determine	what	portion	of	work	time	is	spent	specifically	on	the	female condom 
program.	Include	field	staff	who	are	directly	involved	in	implementing	programs,	as	well	as	administrative	staff.	Also	
estimate the female condom-related time of those who are involved in marketing, promotion, and IEC. A useful way to 
help people think about this is to ask, “If there were no female condom activities, how many hours per week would be 
freed up?” Multiply the percentage of full time devoted to female condoms by the compensation (including fringe and 
allowances) of each staff member. Bear in mind that the actual time spent on the female condom may be very different 
from what is implied in formal job descriptions or payroll records.
4. Promotional materials. By checking invoices or other records, estimate the cost of female condom-related promotional 
materials.
5. Transport and storage. Costs of storing and transporting female condoms to points of sale or distribution may be 
close to zero, as female condoms are often transported along with other items. However, over the course of a year, 
the absence of female condoms might mean that fewer vehicle trips would have to be made. If that is so, estimate the 
number of trips saved and multiply by the cost of each trip, including fuel and driver’s compensation.
6. Research. Any research related to female condom marketing or use should be included. Since surveys often include 
other	issues,	take	the	proportion	of	questions	that	are	specifically	related	to	female	condoms	as	a	proportion	of	
total	questions	and	multiply	by	the	cost	of	the	research	effort.	Since	there	are	fixed	costs	entailed	in	designing	and	
implementing the research, take 50% of the cost derived from the “percent of questions” calculation described above.
7. Generate a unit marginal cost. Add up each of the items two to six above, and divide by the number of female 
condoms distributed during the corresponding time period.
Strictly speaking, the result is not truly a marginal cost. Marginal cost is the cost of providing the next one unit of output. 
Also, marginal costs can vary according to their intended users. Some users may require more persuasion, and thus higher 
marketing costs. Others may be geographically remote and require more transportation costs. The closer this exercise 
is tied to particular users, the more precise and useful the result will be. However, for program planning purposes, the 
approximation generated using this method is useful.
Female Condom Marginal Cost Analysis Primer
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Donors: Donors that support the female condom do so  
with a range of motivations. While a common thread may be to 
reduce the burden of HIV/AIDS, some donors are looking for  
clear evidence of value for money, others are motivated by 
the female empowerment potential of the product, and a few 
consider their backing to be a form of diversification or hedging 
to ensure that the female condom remains one of several 
prevention interventions. There can be overlaps among these 
motivations for an individual donor. Donors will continue 
to pursue their own agendas, but for the sake of HIV/AIDS 
control, funders must ensure that the female condom is 
distributed and promoted to increase the number of HIV cases 
averted in as cost-effective a manner as possible. Several specific 
recommendations are offered for donors: 
• To fund existing programs and potentially new ones, 
a Female Condom Success Fund could be created 
in order to provide incentives for program managers, 
advocates, and academics/researchers to implement, 
support, and evaluate approaches in line with the 
conditions of smarter programming mentioned above.  
• Donors can also support important research gaps that 
are mentioned in this study.  
• The male condom campaigns aimed at the target 
audiences examined in this study — female sex workers, 
women in long-term relationships, and single women 
with multiple partners — must be supported as long 
as the marginal costs of the male condom are not 
prohibitively high. While male condoms may be used 
less by women in longer-term relationships, creative 
efforts that might cost more than present campaigns 
should be directed toward both women and men. With 
more data about the marginal costs of the male condom 
for specific target audiences, program managers could 
inform donors about the best use of resources for either 
male condoms or female condoms to create incremental 
acts of HIV/AIDS averted. 
As for whether donors should invest in research and 
development projects to create new, more affordable female 
condoms that could improve cost-effectiveness, they should  
first consider the behavior of other funders of the female 
condom. If other donors are unwilling to support female 
condom programming in the field, R&D investments that 
yield lower commodity costs may offer little value to the female 
condom overall. The cost-effectiveness modeling suggests that 
R&D improvements would have to be extraordinary to garner 
cost-effectiveness commensurate with the male condom. 
Academics and Researchers: Researchers play an important role 
in the continued exploration of the female condom as a value-
added tool in the fight against HIV/AIDS. There are a number 
of data limitations that these researchers could address:
• Most importantly, the value of the less quantifiable 
benefits of the female condom should be identified  
and inventoried. 
• The marginal costs of both male and female condoms 
by user group were not available through this analysis 
because program managers currently do not collect this 
data. Researchers can work with program managers 
to design research that captures this information and 
then offer guidance about the best way to collect this 
information in the future. 
• As mentioned in the data limitation section, 
additional research on female condom substitution is 
recommended, particularly among different user groups.
• Data on public sector programs is particularly 
weak. Information about programmatic costs from 
government programs is spotty or too general to  
be helpful. 
• Various aspects of the contraceptive benefits of the 
female condom also require better understanding. 
These include the portion of pregnancies that are truly 
unwanted and the contraceptive benefits of competing 
HIV prevention options such as VCT and information, 
education, and communication campaigns.
• Data bearing on the demand for male condoms and 
female condoms and how demand varies with price 
would refine the estimates presented in this study, 
and would allow us to be more specific about the 
relationship between price, uptake, and substitution.
• The cost-effectiveness analysis conducted for this study 
used a model that incorporated data from more than a 
dozen female condom programs, rather than analyzing 
individual programs in depth. To confirm the results 
of this study, researchers can focus on discrete female 
condom programs. 
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